Express News | The world's first non-invasive treatment product for cervical precancerous lesions has completed its initial import shipment.

BreakingsJun 5 22:40

Aphena Pharma's new product 'Xiweita' is about to launch—here are the latest updates.

① As the world's first drug-device combination product, the business model of Xiweita has yet to be validated by the market. Establishing doctors' prescription habits and cultivating patient awareness are no easy tasks, both requiring a lengthy period. Whether it can become a blockbuster product remains to be seen through concrete sales data; ② Currently, Xiweita is continuously expanding its indications, such as CIN1, where the number of existing patients is several times that of CIN2, as well as the field of clearing high-risk HPV at the source of the disease.

cls.cnMay 17 22:27

Yahong Medicine-U (688176): Cevira approved for marketing, entering the innovation realization phase.

The Q1 2026 performance met our expectations. In Q1 2026, the company's revenue was RMB 71.09 million, representing a year-on-year increase of 16.34%; net loss attributable to parent company was RMB 112 million, in line with our expectations. Development trends: Agency business.

CICCMay 4 07:37

Yahong Pharmaceutical: First Quarter Report for 2026 of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.

SZSIApr 30 00:00 · Announcements

First Quarter Report of Jiangsu Yahuang Pharmaceutical Technology Co., Ltd. for 2026

SZSIApr 30 00:00 · Announcements

Aphoenix Pharma Q1 2026 Earnings Report: Revenue of 71.08 Million Yuan, Core Product Approval Marks Turning Point

The first-quarter report published by Yahong Pharmaceuticals in 2026 shows that the company achieved operating revenue of approximately RMB 71.08 million in the first quarter, representing a year-on-year increase of 16.34%. The company’s commercialization strategy 2.0 is proceeding steadily, with sufficient capital reserves (approximately RMB 1.567 billion as of the end of the first quarter of 2026). During the reporting period, APL-1702 (Cevira), the world's first non-invasive treatment product for cervical precancerous lesions, was approved for marketing in China in March 2026, filling a clinical gap. The marketing authorization application for Cevira has been accepted by the European Medicines Agency. Additionally, the blue-light cystoscopy system, SYSTEM BLUE, developed by its partner R.WOLF, became available in 2026.

Gelonghui FinanceApr 29 16:55